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Abstract
Background: Continuous abstinence and retention in treatment for alcohol and drug use disorders are central
challenges for the treatment providers. The literature has failed to show consistent, strong predictors of retention.
Predictors and treatment structure may differ across treatment modalities. In this study the structure was reinforced
by the addition of supervised urine samples three times a week and mandatory daily work/structured education
activities as a prerequisite of inclusion in the program.
Methods: Of 128 patients consecutively admitted to buprenorphine maintenance treatment five patients dropped out
within the first week. Of the remaining 123 demographic data and psychiatric assessment were used to predict
involuntary discharge from treatment and corresponding cumulative abstinence probability. All subjects were
administered the Structured Clinical Interview for DSM-IV-TR, and the Symptom Checklist 90 (SCL-90), the Alcohol Use
Disorder Identification Test (AUDIT), the Swedish universities Scales of Personality (SSP) and the Sense of Coherence
Scale (SOC), all self-report measures. Some measures were repeated every third month in addition to interviews.
Results: Of 123 patients admitted, 86 (70%) remained in treatment after six months and 61 (50%) remained in
treatment after 12 months. Of those discharged involuntarily, 34/62 individuals were readmitted after a suspension
period of three months. Younger age at intake, poly-substance abuse at intake (number of drugs in urine), and
number of conduct disorder criteria on the SCID Screen were independently associated with an increased risk of
involuntary discharge. There were no significant differences between dropouts and completers on SCL-90, SSP, SOC
or AUDIT.
Conclusion: Of the patients admitted to the programme 50% stayed for the first 12 months with continuous
abstinence and daily work. Poly-substance use before intake into treatment, high levels of conduct disorder on
SCID screen and younger age at intake had a negative impact on retention and abstinence.
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Background
A large proportion of patients with substance depen-
dence relapse during or after treatment [1-3]. Identifying
predictors of the risk of relapse in different treatment
models may provide valuable information about what
type of patients need extra services to obtain a satisfac-
tory result in treatment.
In treated samples psychosocial factors, such as peer-
group relationships, family problems, employment, and
social support, predict relapse to opiate use [4]. In an
older meta-analysis of predictors of relapse to opiate
use, it was found that a high level of pre-treatment drug
use, a history of prior treatment, no prior abstinence
from opiates, abstinence from alcohol, depression, high
stress, employment problems, association with substance
abusing peers, short length of treatment, and leaving
treatment prior to completion were all associated with
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any medium, provided the original work is properly cited.relapse [5]. Combined effect sizes were generally small.
A frequently reported important predictor of relapse is
the number of substances in baseline urine toxicology
[e.g. [6,7]].
Another potentially important factor is the presence
or absence of an antisocial personality disorder. Con-
duct disorder (DSM IV-TR) is a precursor of anti-
social personality disorder and a childhood or adoles-
cent CD develops into an adult ASPD in between 30%
and 50% of all cases [8]. A recent meta-analysis found
that antisocial personality disorder is a complex pre-
dictor of outcome. In settings such as therapeutic
communities antisocial personality disorder was a posi-
tive factor in predicting retention, whereas in other
types of treatment, such as outpatient drug-free coun-
selling, it was a negative predictor [9]. Along similar
lines, Daughters and colleagues found that antisocial
patients who were under legal supervision had better
retention in inpatient treatment compared with
patients without an antisocial personality disorder who
were also under legal supervision, and those who were
not under legal supervision. Antisocial patients without
legal supervision had the poorest retention rates [10].
Thus, the significance of antisocial personality disorder
m a yb ed e p e n d e n to nt h et y p eo fs t r u c t u r ep r o v i d e d .
The influence of other personality disorders on reten-
tion and outcome is less well known.
In the review of the international literature on evi-
dence-based treatment of substance abuse, Berglund et.
al. concluded that a) a focus on the substance use, b)
high treatment structure, c) continuous intervention
lasting for at least three months and d) a focus on
comorbidity was associated with effective treatment
interventions in comparison with less effective interven-
tions [11].
One potential predictor that has been studied little in
patients with drug addiction is sense of coherence [12].
The theory of sense of coherence was introduced by
American-Israeli medical sociologist Aaron Antonovsky,
who developed the Sense of Coherence Scale (SOC).
Sense of coherence is believed to be a global orientation
to the world and the personal environment as compre-
hensible, manageable, and meaningful. Antonovsky
claimed that sense of coherence has a significant posi-
tive influence on health. Research generally supports
that the SOC is moderately stable over many years and
has predictive validity for physical and mental health,
after controlling for baseline health [12].
The few studies that have been conducted concerning
the impact of the sense of coherence in substance-
dependent populations have generally yielded relatively
strong relationships between higher sense of coherence
and improvement in substance use problems [13,14], or
lower mortality rates during follow-up [15,16].
T h ea i mo ft h i ss t u d yw a st os t u d yp r e d i c t o r so f
cumulative retention in a consecutive cohort of bupre-
norphine-treated patients with the particular emphasis
on elements reinforcing structure of treatment. Based
on the literature, we assumed that an indication of anti-
social personality disorder, here operationalised by the
number of criteria endorsed for conduct disorder on the
SCID Screen, poly-substance abuse at baseline as mea-
sured by the number of positive urine samples for dif-
ferent illicit drugs in urine analysis at intake, and
severity of self-reported general psychiatric distress
(Global Severity Index) at baseline on the Symptom
Checklist 90 (SCL-90), and extent of subjective sense of
coherence (total raw score) were predictive of attrition
from treatment. It was also hypothesised that a low level
of personality pathology on SSP and a low consumption
of alcohol as measured by AUDIT (total raw score)
would be associated with high retention.
Methods
The study was based on data from a prospective study
of the course of buprenorphine treatment in a highly
structured clinic. Patients in the clinic received mainte-
nance treatment for opiate dependence, either bupre-
norphine alone or buprenorphine/naloxone formulation
tablets to be taken sublingually.
The subjects in the study were consecutively
admitted for treatment between August 2004 and
November 2009. At intake to treatment, patients were
informed of the conditions of treatment and, after
both verbal and written consent, were requested to
provide a urine specimen, and were seen by a senior
consultant psychiatrist who initiated and supervised
the buprenorphine treatment continuously. The treat-
ment staff comprising nurses and a social worker
supervised the daily activities as well as the structure
and contacts with other authorities responsible for the
treatment. There is a continuous and close contact
between the patients and the staff. Work activities and
education were organized through joint collaboration
between representatives from the social insurance,
social welfare, employment agency and the psychiatric
unit at the hospital. This type of collaboration in a
maintenance programme is unique in Sweden.
All subjects who completed at least 4 weeks of treat-
ment and who agreed to be included in the firm struc-
ture of the programme were enrolled. According to the
regulations from the National Board of Health and Wel-
fare (2007) [17] the exclusion criteria for opioid substi-
tution treatment, and thus for the study were as follows:
being younger than twenty years of age, less than one
year of frequent opiate use, florid symptoms of psycho-
sis/history of psychosis or ongoing compulsive treatment
within psychiatry [18].
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through a phase of psychological testing and psychiatric
assessment including psychiatric screening for psychia-
tric symptoms and personality disorders: (SCID-II),
SCL-90, AUDIT, SSP, SOC and a standardized clinical
interview. ICD-10 diagnoses of substance disorder were
issued for all patients admitted. In addition diagnoses of
psychiatric disorders were issued in relation to addi-
tional pharmacological treatment interventions.
The subjects were followed from their admission to
treatment and until they were involuntarily discharged,
or until January 1, 2010. In addition to the supervised
urine samples interviews and tests were repeated every
third months up to one year after admission.
Treatment context
The Buprenorphine clinic is part of the St. Lars psychia-
tric hospital in Southern Sweden, Scania County with an
uptake area of the entire Southern region of Sweden.
Treatment is free for the patients. Patients first attend a
meeting with the unit psychiatrist (PT), the clinic social
worker (LÖ), and a clinic attendant or nurse. Patients
are then offered treatment at the clinic on the basis of
mutual agreements during this meeting and are encour-
aged to begin tapering their use of substances before
admittance for treatment.
The clinic employs abstinence-oriented Buprenorphine
maintenance treatment, in the sense that no illegal drug
use is tolerated after admission to the program. Patients
in Buprenorphine treatment are discharged from treat-
ment if the rules are violated. Violence of all kinds in
the unit, directed at staff or fellow patients, is prohib-
ited, as well as purchasing or dealing drugs during treat-
ment. Criminal activities result in discharge from the
program. The patients must adhere to the ongoing
social and medical case management within the clinic.
This includes participating in drug counselling at their
home town’s counselling services, mostly case-manage-
ment or cognitive behavioural therapy or a Twelve Steps
approach. The amount of counselling is decided by the
home town services.
B e i n gd i s c h a r g e df r o mt h ep r o g r a mr e q u i r e st h a tt h e
positive urine screen at the unit is verified by an inde-
pendent laboratory finding. Urine samples are collected
under surveillance and sent to Lund University Hospi-
tal’s chemical laboratory. If tests are positive for drugs,
they are sent to a second laboratory for a confirmatory
analysis. Urine samples are analyzed using Gas chroma-
tography-mass spectrometry (GC-MS) [19]
Discontinuation of treatment is always decided jointly
by the senior consultant psychiatrist and the staff after
informing the other authorities and the patient. After
three months of suspension the patient may apply for a
renewed treatment. During the suspension period the
patient is seen on an outpatient basis. The aim of that
particular strategy is to maintain contact with the
patient in order to reduce the risk of drug overdose.
The patient is also allowed to continue in his work/
education.
The staff, outpatient counsellors and officials from
social services and from the regional social insurance
office together help the patients to find work, and to
coordinate their work with treatment adherence. All
patients submit three tests per week, and maintain a
fulltime job or fulltime study. After 4 months of treat-
ment, the required urine tests are reduced to one per
week.
All patients who are admitted are administered self-
report tests at intake (see measures below). When
patients score two standard deviations above the age
and gender adjusted norms on the Alcohol Use Disorder
Identification Test (AUDIT), they are routinely offered
pharmacotherapy for alcoholism, generally disulfiram or
acamprosate. Patients scoring above T = 70 on Symp-
tom Checklist 90 (SCL-90) at any time are referred for a
full psychiatric assessment and may be offered pharma-
cotherapy indicated.
During the ongoing treatment patients with non-trea-
table adverse reactions to buprenorphine are referred to
the general opioid agonist maintenance unit at the same
hospital, where methadone is an alternative intervention.
After one month of treatment, patients undergo
assessment for personality disorders with the SCID-II
and SSP (see below). Thus, all patients who are adminis-
tered the SCID-II have been drug free for one month.
Assessments
At intake to treatment patients in the study were asked
to complete the Alcohol Use Disorder Identification
Test (AUDIT), the Sense of Coherence scale (SOC), and
the Symptom Checklist 90 (SCL-90). After one month
of treatment, patients were administered the Structured
Clinical Interview for the DSM-IV-TR (SCID-II) and the
Swedish universities Scales of Personality (SSP). The
SOC and SCL-90 tests were repeated every third month
and AUDIT twice during the first year of study.
The SCID-II and SCID Screen
The Structured Clinical Interview for the DSM-IV- TR,
Axis II (SCID-II) is a widely used semi-structured inter-
view designed to assess personality disorders [20]. The
interview covers the eleven DSM-IV Personality Disor-
ders (including personality disorders not otherwise spe-
cified) and the appendix categories Depressive
Personality Disorder and Passive-Aggressive Personality
Disorder. Patients first complete the self-report ques-
tionnaire and in a subsequent interview the interviewer
asks follow-up questions about items that are endorsed
on the questionnaire. For antisocial personality disorder
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disorder before age 15. If patients satisfy criteria for
conduct disorder, they are asked questions about all cri-
teria for adult antisocial personality disorder.
For the present study the symptom count from the
SCID screen for conduct disorder was used as indicators
of personality disorder-related traits. While there are
advantages with the full interview data for clinical use
(the ability to have a dialogue with the patient and
understand the subjective meaning of the problems
reported), the SCID-questionn a i r ei sl e s ss u s c e p t i b l et o
interviewer bias and has been shown to be highly corre-
lated with symptom counts from the interview with a
correlation of 0.86 between the questionnaire and inter-
view [21], and to be highly stable in drug abusers, with
a test-retest correlation of 0.76 over one year [22].
The Symptom Checklist 90 - SCL-90
The Symptom Checklist-90 (SCL-90) is a self-report
measure of psychiatric symptoms, covering nine differ-
ent symptoms relating to psychiatric conditions. Symp-
toms are rated on a 5 point Likert scale [23]. The
patient responds to each statement (e.g., “nervousness or
shakiness”) to what degree of severity the symptom has
been present in the past week on a 5-point scale (0 “not
at all”,1“al i t t l eb i t ”,2“moderately”,3“quite a bit”,o r
4 “extremely”). For the calculations only the Global
Severity Index, the mean of all items, was used.
The Swedish SCL-90 version was translated and back-
translated into English, and standardized on a nationally
representative sample of 5,000 community residents and
validated against psychiatric samples with relevant diag-
noses and substance abusers (total n = 1,800). On the
basis of the representative sample gender-adjusted T-
scores have been developed. T-scores have a normal
mean of 50 and a standard deviation of 10 [24]. The
cut-off level indicating clinically significant problems
was set to T≥70. These are reported in the descriptive
statistics for the sample.
The Sense of Coherence Scale (SOC)
The Sense of Coherence Scale is a 29-item self-report
scale designed to measure Antonovsky’s construct of
sense of coherence [11]. It is designed to measure a
basic attitude to life, or a personality dimension,
hypothesized to facilitate the ability to cope with stress.
The Swedish standardization and validation is based on
Hansson and Olsson [25].
The Alcohol Use Disorder Identification Test (AUDIT)
The AUDIT is a 10-item scale designed to measure
alcohol related disorders [26] used in a very large num-
ber of both epidemiological and clinical studies. For this
study we report age- and gender-adjusted T-scores
based on a Swedish standardization study [27]. However,
for statistical analyses, we used the unadjusted scores,
since the subjects’ age and gender were also included as
co-variates.
The Swedish universities Scales of Personality (SSP)
The Swedish universities Scales of Personality (SSP) is a
revision of the Karolinska Scales of Personality (KSP).
SSP is published in Sweden but has been translated into
English [28]. The personality profile is presented in T-
score format (mean 50 and standard deviation 10). It
has 91 items and yields 13 personality scales: somatic
trait anxiety, psychic trait anxiety, stress susceptibility,
lack of assertiveness, impulsiveness, adventure seeking,
detachment, social desirability, embitterment, trait irrit-
ability, mistrust, verbal trait aggression and physical
aggression.
Statistical analysis
All statistics were calculated on Stata 11 for Windows.
Cox Proportional Hazard Regression was used to assess
predictors of cumulative retention. All selected predic-
tors (age, gender, number of drugs in urine at baseline,
AUDIT score, criteria count for conduct disorder from
the SCID Screen and SCL-90 global severity index) were
entered in a multivariate analysis. Two patients who
dropped out within the first two days of treatment were
treated as censored observations. We controlled for age
and gender, because two of our covariates are known to
vary substantially by age and gender, namely psychiatric
symptoms [29] and antisocial behaviour [30,31]. We
first estimated a model for each covariate to describe
the univariate relationship between the covariate and
retention. Further, the proportional hazards assumption
for each covariate was tested. The test is a c
2 statistic
with one degree of freedom, where rejection of the null
hypothesis indicates that the effect of a covariate is not
constant over time.
Because there is evidence that dimensional models of
antisocial personality pathology are superior to taxo-
nomic ones, we chose to enter the criteria count rather
than a categorical predictor based on a rationally
derived cut-off for diagnosis that would result in loss of
information on either side of the cut-off [32-34]. For the
statistical predictor analysis raw scores were used.
Ethics approval was obtained from the Regional Ethi-
cal Review Board in Lund (# 847/2004).
Results
Subjects
A total of 128 subjects were originally included. Five
subjects either dropped out within the first weeks or did
not stay long enough to complete the SCID-II and were
excluded from further analyses, leaving 123 subjects. No
statistical comparison of early dropouts with the remain-
ing patients was deemed necessary.
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the remaining subjects 97 were men and 26 were
women. The mean age at admission was 33.5 (range: 22
to 62, SD = 8.6). The mean gender-adjusted T-score for
the SCL-90 Global Severity Index (GSI = 81.3) was 3
standard deviations above the normative gender- and
age-matched mean for the Swedish population. The
mean SOC score was 119 (range: 64 to 191), one stan-
dard deviation below the norm group, and the mean
number of personality disorders according to the SCID-
II interview was 3.2 (range: 0 to 9). A total of 17 had no
personality disorder, 39 had just one personality disor-
der, and the remaining patients had two or more. The
most common personality disorders were antisocial
(74%), narcissistic (56%), schizotypal (40%) and border-
line personality disorder (37%).
Of all patients 67% scored below 60 on the AUDIT T-
score, which indicates scores within the normal-range
and 13% scored above 70 (i.e., two standard deviations
above the age and gender-adjusted mean), indicating
serious alcohol problems.
During the treatment 41 patients (33% of the whole
group) developed psychiatric symptoms indicating need
for additional pharmacological treatment with antipsy-
chotic or/and antidepressant medication. The patients
were prescribed olanzapine (11), mirtazapine (27), cita-
lopram (2) and venlafaxine (1). The average T-scores for
depression in the group undergoing pharmacological
treatment was significantly higher: T = 80 (S.D. = 24.9)
than in the group with no prescribed pharmacological
treatment, T = 69 (S.D. = 19.8), validating the clinical
diagnoses (t121 = 2.66, p < .001). In the group treated
with these specific pharmacological interventions 25
patients of the 41 (61%) completed treatment over the
first 12 months.
Discharge and dropout from treatment
The observation period ranged from two weeks to 64
months. The median survival time was 13 months. In
all, 61 patients (50%) remained in treatment for at least
one year, 6 (5%) ended treatment on their own request
and 56 (45%) were discharged involuntarily. Of the 56
patients who were involuntarily discharged 34 (30%)
were readmitted for a new buprenorphine treatment
after the suspension period and another 13 (11%) have
started in the methadone maintenance program. One
patient died after committing suicide 6 months after
leaving treatment.
The results of the unadjusted and adjusted models are
shown in Table 2. In the columns 2-4 hazard ratios with
confidence intervals are shown from the unadjusted
models. In column 5 the c
2 for violation of the propor-
tional hazards assumption is shown. None of the tests
indicated that the assumption was violated. The tests
SSP and SOC were dropped since there were no signifi-
cant differences between completers and non-comple-
ters on those measures, and the amplitude of the T-
scores were in general within the standard deviation on
the subscale averages.
The multivariate regression was significant (likelihood
ratio X
2
(5) = 22.56, p < 0.002) for the variables: age,
number of drugs in urine and on the conduct disorder
screen. In the multivariate analysis, higher age, poly-sub-
stance abuse, and the number of conduct disorder cri-
teria at intake were significantly associated with
discharge before the ending of the first year.
The relationship is illustrated in Figure 1.
Discussion
The program had a high retention rate compared to
levels reported in other studies [35,36]. Fifty percent of
the patients remained in treatment over the first year
showing high compliance with the treatment goals
demonstrated by negative urine specimens three times a
week and continuous work attendance. In line with
some previous research, baseline poly-substance use pre-
dicted poor response to opiate substitution treatment
[6,7]. The number of drugs in urine at the time of treat-
ment entry was significantly associated with drop-out
Table 1 Descriptive statistics for the cohort at admission
(n = 123)
Mean or
N
Standard
deviation or
%
Women 26 21%
Men 97 79%
Age at admission 33.2 8.5
High school completed 35 30%
Symptom Checklist: SCL-90
Global Severity Index (GSI) T-score 81.8 24.1
SCL-90: Anxiety - T-score 79.8 23.3
SCL-90: Depression - T-score 76.1 21.8
AUDIT T-score 59.1 19.0
Antisocial personality disorder (SCID II) 93 74%
No personality disorder (SCID II) 17 13%
Drugs detected in urine samples at
admission
Amphetamine 17 14%
Benzodiazepines 60 49%
Buprenorphine 56 46%
Cannabis 43 35%
Cocaine 1 1%
Dextropropoxyphene 5 4%
Methadone 8 7%
Opiates 62 50%
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problems staying abstinent over a prolonged period and
increased the risk of discharge in this cohort.
It seems that strategies are needed to support patients
who have a high degree of poly-substance abuse prior to
entering treatment. Other types of treatments like
methadone, residential treatment or alternative interven-
tions may be indicated in some cases. However, it seems
that the one-year level of abstinence associated with
high compliance and good treatment response stands
well in comparison to previous studies of drop-out and
retention in substitution treatment [37].
In line with several other studies, the SCID screen as
an indicator of antisocial traits had a significant impact
on discharge from treatment in this study, even after
controlling for a number of relevant covariates [10,38].
As noted in the introduction, a significant interaction
may exist between structure and type of treatment and
Table 2 Results of Cox Proportional hazard regression
Hazard
ratio
1
Risk ratio 95%
lower limit
Risk ratio 95%
upper limit
Test of proportional odd
assumption c
2(1)
Hazard
ratio
2
Risk ratio 95%
lower limit
Risk ratio 95%
upper limit
ZP
SCL-90 GSI 1.27 0.94 1.73 0.83 1.25 0.88 1.78 1.26 0.21
AUDIT 1.00 0.96 1.04 1.01 0.96 0.92 1.00 -1.83 0.07
Female
gender
1.65 0.81 3.36 0.06 1.57 0.71 3.44 1.12 0.27
Age 1.02 1.00 1.05 0.79 1.05 1.01 1.09 2.71 <0.01
CD count 1.10 1.01 1.20 0.00 1.12 1.02 1.23 2.30 0.02
No of drugs
in urine
1.37 1.11 1.67 0.04 1.34 1.08 1.67 2.65 <0.01
Cumulative Proportion Surviving (Kaplan-Meier)
Complete   Censored
Conduct disorder criteria
___   <= 5
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Figure 1 Survival curve over the first 2000 days in patients with 0-4 criteria, 5-9 criteria and 10 or more criteria on Conduct disorder.
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social personality disorder in particular. The treatment
in the clinic had a clear focus on abstinence, high struc-
ture, high compliance with the treatment regimen, and
the contingency between work attendance and the con-
tinuance of treatment, a format that should be well sui-
ted for patients with co-morbid substance use disorder
and antisocial personality disorder [9,10,39,40]. Even so,
the patients with more severe antisocial personality
traits, as measured by the number of conduct criteria
endorsed, were at increased risk of dropping out of
treatment.
Self-reported symptoms as measured by the SCL-90
were associated with higher but non-significant risk of
involuntary discharge. The results from previous
research have been mixed concerning the impact of
depression and anxiety on involuntary discharge [41].
Patients staying in treatment for at least one year
showed a statistical tendency of p < .10 on the SOC
scale, but SOC was not predictive of treatment
completion.
In a clinical context the findings suggest that a highly
structured and stringently monitored opioid substitution
treatment may be effective for a relatively wide group of
patients with opiate dependence and a high level of psy-
chiatric co-morbidity, including a very high prevalence
of antisocial personality disorder [11]. The work module
in this programme is of particular interest in this regard,
since it is a unique way of increasing structure and pro-
viding a meaningful life situation for the patients. The
level of retention in this study is equivalent to well func-
tioning residential treatment programmes as described
by Bell (1985) [40], and also comparable to levels of
retention in high quality substitution programmes in the
USA and in Europe [35,36].
Strengths and limitations
The present study is based on a cohort of patients con-
secutively admitted for treatment. All patients who were
admitted gave both written and verbal consent, and the
data sets were almost complete. The use of well-vali-
dated instruments to assess conduct disorder and symp-
toms as well as the use of stringent criteria for
treatment success increase the internal validity of this
study.
As regards limitations, it is important to note that the
patients in this study were self-selected for a treatment
that is both abstinence-oriented and oriented towards
full rehabilitation in an outpatient setting. Therefore, the
results may not generalize to treatment modalities with
other treatment goals and a less severe focus on absti-
nence. The size of the sample is another limitation,
especially in terms of studying interactions between
variables.
Conclusions
The buprenorphine program in this study demonstrated
a high level of retention over one year and beyond with
a strict focus on abstinence and work adaptation.
Younger patients and those who reported many symp-
toms of conduct disorder on the SCID-II screen as a
proxy of anti-social personality disorder, had a higher
dropout rate than other patients throughout the study.
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